Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.67 |
| ▸ | NPC1 | O15118 | 7/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29145798 | 0.89 | SMN1; SMN2 (0.55) | RAB9ASMN1; SMN2NPC1HPGDCYP1A2 | |
| SCHEMBL31114389 | 0.87 | SMN1; SMN2 (0.59) | RAB9ASMN1; SMN2NPC1HPGDCYP1A2 | |
| SCHEMBL31173200 | 0.87 | SMN1; SMN2 (0.59) | RAB9ASMN1; SMN2NPC1HPGDCYP1A2 | |
| SCHEMBL11655759 | 0.87 | SMN1; SMN2 (0.80) | RAB9ASMN1; SMN2NPC1HPGDCYP1A2 | |
| SCHEMBL15789054 | 0.86 | RAB9A (0.61) | RAB9ASMN1; SMN2NPC1HPGDCYP1A2 | |
| SCHEMBL7432597 | 0.86 | ALDH1A1 (0.51) | RAB9ASMN1; SMN2NPC1HPGDCYP1A2 | |
| SCHEMBL25736763 | 0.86 | ALDH1A1 (0.57) | RAB9ASMN1; SMN2NPC1HPGDCYP1A2 | |
| SCHEMBL8897098 | 0.85 | NAMPT (0.56) | RAB9ASMN1; SMN2NPC1HPGDCYP1A2 | |
| SCHEMBL7425443 | 0.85 | RAB9A (0.71) | RAB9ASMN1; SMN2NPC1HPGDCYP1A2 | |
| SCHEMBL7427867 | 0.85 | ALDH1A1 (0.53) | RAB9ASMN1; SMN2NPC1HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017216763-A1 | N-PHENYLALKOXY-7-OXO-6-SULFOOXY-1,6-DIAZABICYCLO[3.2.1]OCTANE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | WOCKHARDT LIMITED (IN) | 2017-12-21 | — | — | WO | disclosed |
| US-8962667-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | Microdose Therapeutix, Inc. (US) | 2015-02-24 | — | — | US | disclosed |
| CN-102015651-B | Compounds and compositions as TLR activity modulators | IRM LLC | 2014-12-31 | — | — | CN | disclosed |
| US-20140363395-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | MICRODOSE THERAPEUTX INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8846735-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140072532-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | MICRODOSE THERAPEUTX, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8575205-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| CN-102762226-A | Benzonaphthyridine-containing vaccines | NOVARTIS AG | 2012-10-31 | — | — | CN | disclosed |
| US-20120183498-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | NITZ THEODORE J (US) | 2012-07-19 | — | — | US | disclosed |
| US-8202896-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| WO-2006014185-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2006-02-09 | — | — | WO | disclosed |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2005-12-08 | — | — | US | disclosed |
| EP-1529045-A2 | NEW COMPOUNDS | Astra Zeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| US-6815459-B2 | USE IN PREVENTING VARIOUS MEDICAL DYSFUNCTIONS AND DISEASES ARISING FROM REACTIVE OXYGEN SPECIES, IN PARTICULAR STROKE, PARKINSON'S DISEASE, ALZHEIMER'S DISEASE; LIPID PEROXIDATION INHIBITION ACTIVITY | SAM-SUNG ELECTRONICS CO., LTD. (KR) | 2004-11-09 | — | — | US | disclosed |
| US-20040152699-A1 | Compounds | ASTRAZENECA AND NPS PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004014881-A2 | '1,2,4'OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | ASTRA ZENECA AB (SE) | 2004-02-19 | — | — | WO | disclosed |
| US-20030220337-A1 | Seleno compounds containing nitrone moiety, their preparation and their therapeutic uses | SAM-SUNG ELECTRONICS CO., LTD. (KR) | 2003-11-27 | — | — | US | disclosed |
| US-6639107-B1 | Potentiating glutamate receptor function | ELI LILLY AND COMPANY | 2003-10-28 | — | — | US | disclosed |
| EP-1246797-A1 | CYCLOPENTYL SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001042203-A1 | CYCLOPENTYL SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220337-A1 | Seleno compounds containing nitrone moiety, their preparation and their therapeutic uses | GPX4, GPX1, LPO | RAB9A 455/4885SMN1; SMN2 39/4885NPC1 112/4885 |
| US-20040152699-A1 | Compounds | SDHA, CYP11B2, CYP11B1 | RAB9A 1283/4885SMN1; SMN2 2060/4885NPC1 6/4885 |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRIK5, GRM2 | RAB9A 1926/4885SMN1; SMN2 1409/4885NPC1 554/4885 |
| US-20140072532-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | TTPA, HAVCR2, ZC3HAV1 | RAB9A 2841/4885SMN1; SMN2 1129/4885NPC1 223/4885 |
| US-20140363395-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | TTPA, HAVCR2, ZC3HAV1 | RAB9A 2841/4885SMN1; SMN2 1129/4885NPC1 223/4885 |
| US-20120183498-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | TTPA, HAVCR2, ZC3HAV1 | RAB9A 2841/4885SMN1; SMN2 1129/4885NPC1 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.